Works matching IS 11732563 AND DT 2023 AND VI 43 AND IP 4

Results: 9

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 299, doi. 10.1007/s40261-023-01258-7

By:

De Greef, Axel;
Ghislain, Pierre-Dominique;
Bulinckx, Audrey;
Coster, Alison;
de Halleux, Céline;
Damsin, Thomas;
Jacobs, Marie-Claude;
Suys, Erwin;
Zoghaib, Samer;
Baeck, Marie

Publication type:

Article

Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 307, doi. 10.1007/s40261-023-01257-8

By:

Prinz, Carolin;
Streit, Frank;
Schumann, Christian;
Dudakova, Anna;
Lanckohr, Christian;
Schanz, Julie;
Bohn, Matthias;
Groß, Uwe;
Meissner, Konrad;
Moerer, Onnen;
Harnisch, Lars-Olav

Publication type:

Article

Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 209, doi. 10.1007/s40261-023-01256-9

By:

Zheng, Zhigui;
He, Dongyuan;
Chen, Jianguo;
Xie, Xiaohui;
Lu, Yunan;
Wu, Binbin;
Jiang, Xinxin

Publication type:

Article

A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 251, doi. 10.1007/s40261-023-01255-w

By:

Jiang, Yanqing;
Liu, Ruizhe;
Xuan, Jianwei;
Lin, Sisi;
Zheng, Qiang;
Pang, Jianxin

Publication type:

Article

Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 289, doi. 10.1007/s40261-023-01254-x

By:

Shin, Young Eun;
Kumar, Arun;
Guo, Jeff Jianfei

Publication type:

Article

Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 241, doi. 10.1007/s40261-023-01253-y

By:

Yu, Xiangyou;
Hao, Yan;
Zhu, Zhanfang;
Zhang, Wei;
Liu, Bo;
Ma, Meijuan;
Zhang, Xuejun;
Wei, Na;
Wang, Junkui;
Liu, Fuqiang

Publication type:

Article

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 277, doi. 10.1007/s40261-023-01252-z

By:

D'Haens, Geert;
Reinisch, Walter;
Schreiber, Stefan;
Cummings, Fraser;
Irving, Peter M.;
Ye, Byong Duk;
Kim, Dong-Hyeon;
Yoon, SangWook;
Ben-Horin, Shomron

Publication type:

Article

Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 227, doi. 10.1007/s40261-023-01251-0

By:

Gonzalez-Fierro, Aurora;
Romo-Pérez, Adriana;
Chávez-Blanco, Alma;
Dominguez-Gomez, Guadalupe;
Duenas-Gonzalez, Alfonso

Publication type:

Article

Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.

Published in:

Clinical Drug Investigation, 2023, v. 43, n. 4, p. 265, doi. 10.1007/s40261-023-01249-8

By:

Wang, Zhe;
Lou, Yake;
Wang, Qi;
Sun, Min;
Li, Xiaonan;
Wang, Yinghui;
Wang, Yuehui

Publication type:

Article